Business
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.,
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. (\"Protagonist\" or the \"Company\") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a presentation and host one-on-one meetings with investors at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8-11, 2024.Event: 42nd Annual J.P. Morgan Healthcare ConferenceDate: January 8-11, 2024Presentation: Tuesday, January 9 at 9:45-10:25 A.M. PSTLocation: Elizabethan C, The Westin St. Francis, San Francisco, CAWebcast Link: https://jpmorgan.metameetings.net/events/healthcare24/sessions/49448-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=trueIf you are interested in meeting with the Protagonist management team, please contact your J.P. Morgan representative.A replay of the company presentation will be published to the Events & Presentations section of the Protagonist corporate website: https://www.protagonist-inc.com/events-presentations.About ProtagonistProtagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist scientists jointly discovered PN-235 (now known as JNJ-2113) as part of Protagonist's Interleukin-23 receptor (IL-23R) collaboration with Johnson & Johnson and followed it through IND-enabling pre-clinical and Phase 1 studies, with Johnson & Johnson assuming responsibility for further clinical development. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program. The randomized portion of the Phase 2 REVIVE study was unblinded, showing positive results and is now complete, with an open-label extension underway. The global Phase 3 VERIFY study of rusfertide in polycythemia vera is ongoing. Protagonist retains all worldwide development and commercialization rights to rusfertide.More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at protagonist-inc.com.Investor Relations ContactCorey Davis, Ph.D.LifeSci Advisors+1 212 915 [email protected] Relations ContactVirginia AmannENTENTE N...